46834-36-0

Usage

Uses

Used in Pharmaceutical Industry:
1,3-Benzenediol, 5-nonylis used as an inhibitor of colon cancer cell growth and proteasome activity. 1,3-Benzenediol, 5-nonylhas been studied for its potential to suppress the proliferation of colon cancer cells, making it a promising candidate for cancer therapeutics.
Used in Research Applications:
1,3-Benzenediol, 5-nonylis also utilized in research settings to investigate the inhibitory activities of alkylresorcinols against various types of cancer cells. This helps in understanding the underlying mechanisms of action and their potential applications in cancer treatment and prevention.

Upstream product

• 59968-08-0 1,3-dimethoxy-5-(non-1-yl)benzene 
• 61621-53-2 2,4,6-Tribromo-5-nonyl-benzene-1,3-diol 
• 629-05-0 n-octyne 
• 26153-38-8 3,5-dihydroxybenzaldehyde 
• 187803-40-3 3,5-bis(tert-butyldimethylsilyloxy)benzaldehyde 
• 252913-16-9 1,3-bis(tert-butyldimethylsilyloxy)-5-[(Z)-2'-nonenyl]benzene 
• 252913-15-8 1-[3,5-bis-(tert-butyldimethylsilanyloxy)phenyl]non-2-yn-1-ol 
• 17049-49-9 octylmagnesium bromide 
• 61621-52-1 5-n-Nonyl-1,3-cyclohexandion 
• 61621-49-6 2-Nonyl-4,6-dioxo-cyclohexanecarboxylic acid ethyl ester 
• 78217-11-5 dodec-2-enoic acid ethyl ester 
• 634922-42-2 1-(3,5-dimethoxyphenyl)nonan-1-ol 
• 17213-57-9 3,5-dimethoxybenzoyl chloride 
• 756499-46-4 1,3-bis-(tert-butyldimethylsilanyloxy)-5-nonylbenzene 

Relevant academic research and scientific papers

COMPOUNDS HAVING AGONISTIC EFFECT AGAINST GPR84, PREPARATION METHOD FOR COMPOUNDS AND USE OF COMPOUNDS

The present invention relates to a class of compounds represented by the formula I, or pharmaceutically acceptable salts thereof, methods for their preparation, and application as small molecule tools that function as GPR84 agonists, and their use in preparing a medicament for the treatment of septicemia.

Synthesis and inhibitory activities against colon cancer cell growth and proteasome of alkylresorcinols

We have identified alkylresorcinols (ARs) as the major active components in wheat bran against human colon cancer cell growth (HCT-116 and HT-29) using a bioassay-guided approach. To further study the structure-activity relationships, 15 ARs and their intermediates (1-15) were synthesized expediently by the modified Wittig reaction in aqueous media, and six 5-alkylpyrogallols and their analogues (16-21) were prepared by the general Grignard reaction. The synthetic AR analogues were evaluated for activities against the growth of human colon cancer cells HCT-116 and HT-29 and the chymotrypsin-like activity of the human 20S proteasome. Our results found that (1) AR C13:0 and C15:0 (13 and 14) had the greatest inhibitory effects in human colon cancer cells HCT-116 and HT-29, while decreasing or increasing the side chain lengths diminished the activities; (2) two free meta-hydroxyl groups at C-1 and C-3 on the aromatic ring of the AR analogues greatly contributed to their antitumor activity; (3) the introduction of a third hydroxyl group at C-2 (20 and 21) into the aromatic ring of the AR analogues yielded no significant enhancement in activity against HCT-116 cells and decimated the effects against HT-29 cells, but dramatically increased the activity against the chymotrypsin-like activity of the human 20S proteasome; and (4) AR C11:0 (12) was found to have the greatest effect in a series of AR C9:0-C17:0 against the chymotrypsin-like activity of the human 20S proteasome.

Climacostol, a defense toxin of Climacostomum virens (protozoa, ciliata), and its congeners

Climacostol (1), a defense toxin of the heterotrich ciliate Climacostomum virens was established as 5-(Z)-non-2-enyl-benzene-1,3-diol. The structure was rigorously confirmed by the total synthesis. The two congeners of climacostol contained in this ciliat